Indications
Each indication opens its study.
Metabolic Diseases
CNS & addiction
Stage of development
-
- Molecule
- PNB-081
- Indication
- Obesity
- Biological action
- CCK-mediated reduction of food intake
- Status
- IND ready
-
PNB-081
Opiate ManagementCCK-A antagonist
- Molecule
- PNB-081
- Indication
- Opiate Management
- Biological action
- CCK-A antagonist
- Status
- IND ready
- Target and mechanism
- CCK-A (CCK1) antagonist, with a binding profile equivalent to devazepide. Developed from PNB-001.
- Key findings
In metabolic-cage studies, food intake in rats fell from day 2 onwards, by up to 50% (group of six rats). A 2 mg/kg dose lowered blood glucose in the glucose tolerance test.
Given orally at 1 mg/kg in mice alongside 4 mg/kg morphine, it prevented the development of morphine tolerance over many days.
Also effective in preclinical models of Pancreatitis, depression and anxiety.
- Development
Orally bioavailable, with very high membrane penetration and favourable CaCo-2 permeability and plasma protein binding.
- Intellectual property
- Protected until 2037, including a five-year extension, in most countries.
Interested in a programme?
PNB Vesper welcomes discussions on clinical development, licensing, co-development and investment for any molecule in the pipeline.
